Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 3616

1.

Expected population impacts of discontinued prostate-specific antigen screening.

Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, Cooperberg MR.

Cancer. 2014 Jul 25. doi: 10.1002/cncr.28932. [Epub ahead of print]

PMID:
25065910
[PubMed - as supplied by publisher]
2.

[CONs].

Sobue T.

Gan To Kagaku Ryoho. 2014 May;41(5):553-7. Japanese.

PMID:
24917002
[PubMed - indexed for MEDLINE]
3.

[Future perspectives on screening for prostate cancer - an experienced Urologist's viewpoint].

Ito K.

Gan To Kagaku Ryoho. 2014 May;41(5):545-52. Japanese.

PMID:
24917001
[PubMed - indexed for MEDLINE]
4.

Enzalutamide in metastatic prostate cancer before chemotherapy.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators.

N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1.

PMID:
24881730
[PubMed - indexed for MEDLINE]
5.

Racial Disparities in Prostate Cancer-Specific Mortality in Men With Low-Risk Prostate Cancer.

Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Hoffman KE, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL.

Clin Genitourin Cancer. 2014 May 9. pii: S1558-7673(14)00081-0. doi: 10.1016/j.clgc.2014.04.003. [Epub ahead of print]

PMID:
24861952
[PubMed - as supplied by publisher]
6.

CtBP2 could promote prostate cancer cell proliferation through c-Myc signaling.

Zhang C, Gao C, Xu Y, Zhang Z.

Gene. 2014 Aug 1;546(1):73-9. doi: 10.1016/j.gene.2014.05.032. Epub 2014 May 14.

PMID:
24835310
[PubMed - indexed for MEDLINE]
7.

RE: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.

Carlsson S, Roobol MJ, Schröder FH, Hugosson J, Auvinen A.

J Natl Cancer Inst. 2014 Apr 26;106(5). pii: dju079. doi: 10.1093/jnci/dju079. No abstract available.

PMID:
24771874
[PubMed - indexed for MEDLINE]
8.

Response.

Haines IE, Miklos GL.

J Natl Cancer Inst. 2014 Apr 26;106(5). pii: dju081. doi: 10.1093/jnci/dju081. No abstract available.

PMID:
24771873
[PubMed - indexed for MEDLINE]
9.

Obesity and Long-Term Survival after Radical Prostatectomy.

Chalfin HJ, Lee SB, Jeong BC, Freedland SJ, Alai H, Feng Z, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M.

J Urol. 2014 Apr 21. pii: S0022-5347(14)03421-1. doi: 10.1016/j.juro.2014.04.086. [Epub ahead of print]

PMID:
24769031
[PubMed - as supplied by publisher]
10.

Prostate cancer deaths and incident cases among American Indian/Alaska Native men, 1999-2009.

Hoffman RM, Li J, Henderson JA, Ajani UA, Wiggins C.

Am J Public Health. 2014 Jun;104 Suppl 3:S439-45. doi: 10.2105/AJPH.2013.301690. Epub 2014 Apr 22.

PMID:
24754659
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer.

Ritch CR, You C, May AT, Herrell SD, Clark PE, Penson DF, Chang SS, Cookson MS, Smith JA Jr, Barocas DA.

Urology. 2014 Jun;83(6):1309-15. doi: 10.1016/j.urology.2014.02.023. Epub 2014 Apr 18.

PMID:
24746665
[PubMed - indexed for MEDLINE]
12.

Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysis.

Zhu Z, Zhang J, Liu Y, Chen M, Guo P, Li K.

Br J Cancer. 2014 May 13;110(10):2396-404. doi: 10.1038/bjc.2014.197. Epub 2014 Apr 15.

PMID:
24736585
[PubMed - indexed for MEDLINE]
13.

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.

Angelergues A, Maillet D, Fléchon A, Ozgüroglu M, Mercier F, Guillot A, Le Moulec S, Gravis G, Beuzeboc P, Massard C, Fizazi K, de La Motte Rouge T, Delanoy N, Elaidi RT, Oudard S.

Eur J Cancer. 2014 Jun;50(9):1602-9. doi: 10.1016/j.ejca.2014.03.015. Epub 2014 Apr 8.

PMID:
24725337
[PubMed - indexed for MEDLINE]
14.

Clinical presentation of prostate cancer in black South Africans.

Tindall EA, Monare LR, Petersen DC, van Zyl S, Hardie RA, Segone AM, Venter PA, Bornman MS, Hayes VM.

Prostate. 2014 Jun;74(8):880-91. doi: 10.1002/pros.22806. Epub 2014 Apr 9.

PMID:
24723425
[PubMed - indexed for MEDLINE]
15.

Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer.

de Liaño AG, Reig O, Mellado B, Martin C, Rull EU, Maroto JP.

Br J Cancer. 2014 Apr 29;110(9):2201-8. doi: 10.1038/bjc.2014.189. Epub 2014 Apr 10.

PMID:
24722180
[PubMed - indexed for MEDLINE]
16.

Maximal testosterone suppression in prostate cancer--free vs total testosterone.

Rove KO, Crawford ED, Perachino M, Morote J, Klotz L, Lange PH, Andriole GL, Matsumoto AM, Taneja SS, Eisenberger MA, Reis LO.

Urology. 2014 Jun;83(6):1217-22. doi: 10.1016/j.urology.2014.02.001. Epub 2014 Apr 6. Review.

PMID:
24713136
[PubMed - indexed for MEDLINE]
17.

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.

Carlsson S, Assel M, Sjoberg D, Ulmert D, Hugosson J, Lilja H, Vickers A.

BMJ. 2014 Mar 28;348:g2296. doi: 10.1136/bmj.g2296.

PMID:
24682399
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Changes in patterns of practice for prostate cancer radiotherapy in Italy 1995-2003. A survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society.

Pegurri L, Buglione M, Girelli G, Guarnieri A, Meattini I, Ricardi U, Mangoni M, Gabriele P, Bellavita R, Krengli M, Bonetta A, Cagna E, Bunkheila F, Borghesi S, Signor M, Di Marco A, Bertoni F, Stefanacci M, Gatta R, De Bari B, Magrini SM.

Tumori. 2014 Jan-Feb;100(1):31-7. doi: 10.1700/1430.15812.

PMID:
24675488
[PubMed - indexed for MEDLINE]
19.

Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival.

Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ.

Prostate. 2014 Jun;74(8):820-8. doi: 10.1002/pros.22788. Epub 2014 Mar 26.

PMID:
24668612
[PubMed - indexed for MEDLINE]
20.

The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study.

Rusthoven CG, Carlson JA, Waxweiler TV, Raben D, Dewitt PE, Crawford ED, Maroni PD, Kavanagh BD.

Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1064-73. doi: 10.1016/j.ijrobp.2014.01.008.

PMID:
24661660
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk